Search Results

Your search for James H. Doroshow, MD matches 2 pages

Showing 1 - 2

By The ASCO Post Staff / Friday, July 13, 2018 2:23 PM

NCI and VA Launch NAVIGATE to Boost Veterans’ Access to Cancer Clinical Trials

Veterans with cancer who receive treatment from the U.S. Department of Veterans Affairs (VA) will now have easier access to clinical trials of novel cancer treatments, thanks to an agreement between the VA and the National Cancer Institute (NCI), part of the National Institutes of Health. The NCI...

issues in oncology

By James H. Doroshow, MD / 2015 ASCO Annual Meeting

James H. Doroshow, MD, on The NCI’s MATCH Trial

James H. Doroshow, MD, of the National Cancer Institute, describes a new precision medicine initiative called the MATCH trial: Molecular Analysis for Therapy Choice. In 2,400 NCI clinical trial sites, 3,000 patients will be screened and their tumors analyzed to determine whether they contain...

Apr

Today In Oncology

Search Results

Your search for James H. Doroshow, MD matches 2 pages

NCI and VA Launch NAVIGATE to Boost Veterans’ Access to Cancer Clinical Trials

James H. Doroshow, MD, on The NCI’s MATCH Trial

Alectinib Approved as Adjuvant Treatment for ALK-Positive Non–Small Cell Lung Cancer

Professional Societies Introduce New Evidence-Based Guidelines on Testing Immunotherapy Biomarkers in NSCLC

Accelerated Aging May Be a Risk Factor for Early-Onset Cancers in Younger Generations

Novel MDM2 Inhibitor Shows Activity in Salivary Gland Cancers

Novel SPECT/CT Imaging Technique Under Study in Prostate Cancer